Loading
NASDAQHealthcareBiotechnology
Latest quote
$259.86
−$3.69 · -1.40%
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
Latest quote
$259.86
−$3.69 · -1.40%
After-hours
$260.3
+$0.44 · +0.17%
Oct 9, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
Day range
Current $259.86
52-week range
Current $259.86
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
30
Expensive
Sentiment
75
Bullish
Risk
60
Elevated Risk
Momentum
68
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
Day range
Current $259.86
52-week range
Current $259.86
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 8.55M USD | 2.45M USD | — | — |
| Cost of goods sold | 140K USD | 152.41M USD | 86.77M USD | 154.44M USD | — |
| Gross profit | −140K USD | −143.86M USD | −84.32M USD | −154.44M USD | — |
| Research and development | 267.12M USD | 152.41M USD | 86.77M USD | 155.04M USD | 120.26M USD |
| Selling, general, and administrative | 59.08M USD | 56.31M USD | 42.05M USD | 59.55M USD | 47.08M USD |
| Operating expenses | 326.06M USD | 56.31M USD | 42.05M USD | 60.55M USD | 167.33M USD |
| Interest income | 22.93M USD | 17.35M USD | — | — | — |
| Depreciation and amortization | 140K USD | 358K USD | 432K USD | 419K USD | 182K USD |
| Operating income | −326.2M USD | −200.17M USD | −126.37M USD | −214.99M USD | −167.33M USD |
| Net income | −303.27M USD | −182.82M USD | −123.28M USD | −214.03M USD | −167.06M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$603.83
132.37% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Nov 29, 2023 | 1:15 | — | — |
Effective Nov 29, 2023
1:15
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI310.79M0.01%2.3T USD0.03%$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB224.73M0.12%185.3B USD0.03%$289.48+0.64%
iShares Russell 2000 ETFIWM174.37M0.22%77.7B USD0.19%$278.94+0.49%
Vanguard Morningstar Small-Cap Value ETFVBR134.33M0.20%68.2B USD0.05%$234.43+0.22%
State Street SPDR S&P Biotech ETFXBI117.01M1.16%10.11B USD0.35%$153.77+3.00%
Vanguard Extended Market ETFVXF106.66M0.11%95.4B USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO61.19M0.44%14.04B USD0.24%$356.78+0.94%
iShares Biotechnology ETFIBB53.63M0.51%10.41B USD0.44%$206.49+3.00%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap Value ETFVBRState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
